TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05885828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Description: After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Description: After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional diabetic diet
Description: Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up visit every 1-2 years
Description: Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up visit every 1-2 years
Description: Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
Study: NCT05224401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivmecillinam and amoxicillin/clavulanic acid
Description: 1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility
Description: Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
Study: NCT05752435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
Description: comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS
Description: comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
Study: NCT06534931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High velocity low amplitude thoracic spine manipulation
Description: Participants were supine on a treatment table. The chiropractor determined levels of apparent spinal dysfunction by means of static palpation. Participants were then asked to curl forward and bring their knees to their chest as the chiropractor placed a fist just inferior to the targeted level, anywhere between the T4 - T10 vertebrae. The participant was instructed to inhale and then exhale, at which point the chiropractor lowered the participant's torso back to the table and delivered a thrust using his body into his fist.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A previously validated physiologically inert manual procedure to the thoracic spine
Study: NCT04234555

Intervention type: DIAGNOSTIC_TEST
Intervention: Corticomotor excitability to the pelvic floor muscles
Description: Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.

Intervention type: DIAGNOSTIC_TEST
Intervention: Corticomotor excitability to the pelvic floor muscles
Description: Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.

Intervention type: DIAGNOSTIC_TEST
Intervention: Corticomotor excitability to the pelvic floor muscles
Description: Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic floor muscle response to pressure applied at the vulvar vestibule
Description: Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
Study: NCT03852420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUMINIZE RF Balloon Catheter
Description: Ablation Therapy with the LUMINIZE RF Balloon Catheter
Study: NCT06088667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial mobilization group
Description: In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial mobilization group
Description: In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
Study: NCT06645119

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Whey Protein Supplement
Description: Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Supplement
Description: Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.
Study: NCT06545175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracochlear application of VSF1.01
Description: During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
Study: NCT05971355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimpiAD cream 2,5% plus
Description: A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emollient
Description: Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
Study: NCT05425264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-exercise
Description: Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
Study: NCT06245109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral
Study: NCT05994092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Isocapnic Hyperpnea
Description: The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
Study: NCT05644080

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA I&T
Description: Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
Study: NCT04987983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental SLP-R
Description: SLP-R will be given to the infant during bottle-feeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental SLP-L
Description: SLP-L will be given to the infant during bottle-feeding.
Study: NCT06068608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM005
Description: single,intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM005
Description: single,intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNM005
Description: single,intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single,intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single,intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single,intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single,intramuscular injection
Study: NCT04950153

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer navigation
Description: Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SMS Text messaging
Description: Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Media Engagement
Description: HIV testing outreach using social media platforms to promote HIV testing.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Testing Peer Navigation
Description: Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
Study: NCT05470166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline IV
Description: saline infusion same volume as lidocaine
Study: NCT05172297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Web
Description: Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Web
Description: Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
Study: NCT05227326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCNA Inhibitor AOH1996
Description: Given PO
Study: NCT05468606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA2
Description: GA2 sporozoites administered by 50 mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA2
Description: GA2 sporozoites administered by 50 mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA2
Description: GA2 sporozoites administered by 50 mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GA2
Description: GA2 sporozoites administered by 50 mosquito bites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: 0.1 mL BCG vaccine intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF-17D (fractional ID dose)
Description: 0.1 mL YF17D vaccine intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 250mg imiquimod 5% cream topical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mock immunization
Description: 50 bites by uninfected mosquitoes
Study: NCT05912751

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Then Foam Roll
Description: Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.

Intervention type: OTHER
Group type: OTHER
Intervention: Foam Roll Then Exercise
Description: Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
Study: NCT06183710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Psychosocial intervention
Study: NCT04766437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 10mg
Description: Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
Study: NCT05481294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transpersonal Supportive Coaching
Description: Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Support
Description: Standard support is given for four months using a support system provided by Peer Support Foundation
Study: NCT05478343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM21 CAR-T cells
Description: IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
Study: NCT05313932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Participants wake after six hours so that they are deprived of 2 hours of sleep
Study: NCT05022771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015 Dose 1
Description: Dose level 1 of PMG1015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015 Dose 2
Description: Dose level 2 of PMG1015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015 Dose 3
Description: Dose level 3 of PMG1015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015 Dose 4
Description: Dose level 4 of PMG1015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015 Dose 5
Description: Dose level 5 of PMG1015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMG1015 Dose 6
Description: Dose level 6 of PMG1015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study: NCT04234555

Intervention type: DIAGNOSTIC_TEST
Intervention: Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)
Description: Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
Study: NCT05643716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
Study: NCT05279638

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ATG5
Description: This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ATG5
Description: This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
Study: NCT06570980

Intervention type: DRUG
Intervention: sulfonylurease with metformin, DPP4 inhibitors with Metformin
Description: Oral hypoglycemic agents

Intervention type: DRUG
Intervention: sulfonylurease with metformin, DPP4 inhibitors with Metformin
Description: Oral hypoglycemic agents
Study: NCT04941885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
Description: Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
Study: NCT06539481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide 190 micrograms
Description: ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
Study: NCT06197724

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography
Study: NCT05540483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with Zimberelizumab
Description: Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
Study: NCT04321655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity LASER Therapy (HILT)
Description: The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen Gel Phonophoresis (IGP)
Description: Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy (CPT)
Description: 1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)